HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Upregulation of Vascular Endothelial Growth Factor in Amniotic Fluid Stem Cells Enhances Their Potential to Attenuate Lung Injury in a Preterm Rabbit Model of Bronchopulmonary Dysplasia.

AbstractBACKGROUND:
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects extremely preterm infants and remains - despite improvements in neonatal intensive care - a major cause of neonatal mortality and morbidity. Cell-therapeutic strategies employing mesenchymal stem cells (MSC) have been shown to modulate lung development in BPD models.
OBJECTIVE:
Herein, we evaluate the potential of human amniotic fluid (hAF)-SC and hAF-SC with upregulated expression of vascular endothelial growth factor (VEGF) as cell-therapeutic agents for BPD.
METHODS:
Preterm rabbit pups were raised in normoxia (21% O2) or hyperoxia (≥95% O2). Hyperoxia-exposed pups randomly received an intraperitoneal injection of fibroblasts, naïve hAF-SC, or hAF-SC-VEGF on postnatal day (PN) 0. On PN7, surviving pups were tested for pulmonary (forced oscillation technique) and vascular (pulmonary artery Doppler ultrasound) function, and lungs were processed for morphometric measurements of parenchymal and vascular structure and inflammation.
RESULTS:
Intraperitoneal injection of cells resulted in homing to the lungs. The lungs of hyperoxia-exposed animals displayed parenchymal and vascular structural and functional damage reminiscent of BPD, which was significantly improved after treatment with hAF-SC-VEGF. Treating hyperoxia-exposed animals with naïve AF-SC attenuated only the lung inflammation and the vascular structural defect. Treatment with fibroblasts, which were used as a cellular control, did not lead to any improvements.
CONCLUSION:
hAF-SC with upregulated VEGF expression display enhanced potential to prevent/reverse lung injury in preterm rabbits, whereas naïve hAF-SC only show a moderate therapeutic potential. These results point towards an added value of VEGF delivered by hAF-SC in the treatment of BPD.
AuthorsJulio Jiménez, Flore Lesage, Jute Richter, Taro Nagatomo, Thomas Salaets, Silvia Zia, Marina Gabriela Mori Da Cunha, Jeroen Vanoirbeek, Jan A Deprest, Jaan Toelen
JournalNeonatology (Neonatology) Vol. 113 Issue 3 Pg. 275-285 ( 2018) ISSN: 1661-7819 [Electronic] Switzerland
PMID29393249 (Publication Type: Journal Article)
Copyright© 2018 S. Karger AG, Basel.
Chemical References
  • Vascular Endothelial Growth Factor A
Topics
  • Amniotic Fluid (cytology)
  • Animals
  • Animals, Newborn
  • Bronchopulmonary Dysplasia (etiology, therapy)
  • Hyperoxia
  • Hypertension, Pulmonary (complications)
  • Lung (pathology)
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells (cytology, metabolism)
  • Pulmonary Alveoli (physiology)
  • Rabbits
  • Random Allocation
  • Up-Regulation
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: